Current Opinion in Oncology最新文献_第2页

From basic to clinical and therapeutic insights: news on actinic keratosis and skin squamous cell carcinoma.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2024-12-23 DOI: 10.1097/CCO.0000000000001115

Carmen Orte Cano, Mariano Suppa, Ievgenia Pastushenko, Véronique Del Marmol

{"title":"From basic to clinical and therapeutic insights: news on actinic keratosis and skin squamous cell carcinoma.","authors":"Carmen Orte Cano, Mariano Suppa, Ievgenia Pastushenko, Véronique Del Marmol","doi":"10.1097/CCO.0000000000001115","DOIUrl":"10.1097/CCO.0000000000001115","url":null,"abstract":"Purpose of review: Squamous cell carcinoma (SCC) is the second most common skin cancer, with an increasing incidence. This review highlights this past year's advances regarding the understanding of its pathogenesis, newly introduced diagnostic methods and updates in prevention and treatment.Recent findings: While the pathogenesis of SCC progression remains unclear, new sequencing techniques are helping to better characterize these tumours at the molecular level. Recently introduced noninvasive imaging techniques are rapidly transforming SCC diagnosis and follow-up. Although nicotinamide has not demonstrated significant benefit in reducing SCC incidence among transplant recipients, larger studies are needed to achieve statistical power. Tirbanibulin, a new field treatment for actinic keratosis is now available and well tolerated for use in areas up to 100 cm 2 . Surgery remains the cornerstone of SCC treatment and can now be complemented with cemiplimab, when advanced.Summary: Recent years have seen a diagnostic revolution in dermatology, driven by noninvasive imaging and artificial intelligence; however, the physiopathogenesis of SCC progression remains poorly understood. In treatment, immune checkpoint inhibitors have shown good survival outcomes for advanced SCC. Research continues in the neoadjuvant setting and among transplanted patients, with encouraging preliminary results.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"105-109"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of the microbiome in skin cancer development and treatment.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-22 DOI: 10.1097/CCO.0000000000001120

Anthony Martin Fuentes

{"title":"The role of the microbiome in skin cancer development and treatment.","authors":"Anthony Martin Fuentes","doi":"10.1097/CCO.0000000000001120","DOIUrl":"10.1097/CCO.0000000000001120","url":null,"abstract":"Purpose of review: Recent research underscores the significant influence of the skin and gut microbiota on melanoma and nonmelanoma skin cancer (NMSC) development and treatment outcomes. This review aims to synthesize current findings on how microbiota modulates immune responses, particularly enhancing the efficacy of immunotherapies such as immune checkpoint inhibitors (ICIs).Recent findings: The microbiota's impact on skin cancer is multifaceted, involving immune modulation, inflammation, and metabolic interactions. Beneficial strains like Bifidobacterium and Lactobacillus have shown potential in supporting anti-PD-1 and anti-CTLA-4 therapies by promoting T-cell activation and immune surveillance. Evidence from preclinical and clinical studies, including fecal microbiota transplantation (FMT), highlights improved response rates in patients with microbiota-rich profiles. Notably, certain bacterial metabolites, such as inosine, contribute to enhanced antitumor activity by stimulating IFN-γ in CD8 + T cells.Summary: Understanding the interplay between microbiota and skin cancer treatment opens promising avenues for adjunctive therapies. Probiotic and prebiotic interventions, FMT, and microbiota modulation are emerging as complementary strategies to improve immunotherapy outcomes and address treatment resistance in melanoma and NMSC.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"121-125"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term immune related adverse events.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2024-12-16 DOI: 10.1097/CCO.0000000000001113

Leo Plaçais, Olivier Lambotte

引用次数: 0

Chemotherapy-induced nausea and vomiting: can we do better?

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-22 DOI: 10.1097/CCO.0000000000001114

Florian Scotté

{"title":"Chemotherapy-induced nausea and vomiting: can we do better?","authors":"Florian Scotté","doi":"10.1097/CCO.0000000000001114","DOIUrl":"10.1097/CCO.0000000000001114","url":null,"abstract":"Purpose of review: Although the management of nausea and vomiting induced by cancer treatments has evolved, several questions remain unanswered.Recent findings: New antiemetics have been developed these last decades with therapeutic indications to be defined according to the anticancer regimen and partly as a consequence of the assessment of individual patient risk factors. Guidelines still seem to have a low level of knowledge and compliance, with a role for scientific societies in term of dissemination and education. A number of persistent issues relating to emesis still need improvement in prevention and management. Nausea remains a subjective semantic whose evaluation should possibly benefit from educational programs. The risk classification of anticancer drugs must be regularly updated, requiring regular literature reviews and the integration of data from clinical trials relating to emerging anticancer drugs. Recent data, particularly in the context of emerging drugs, highlight the importance to consider emesis' impact beyond the 5-day period, with a potential adaptation of antiemetic prophylaxis, including the mode of administration of oral drugs.Summary: Guidelines update is presented with literature answers to the current issues in order to improve quality of patient's management in the context of emesis related to anticancer therapies.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"158-162"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial introductions.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-02-06 DOI: 10.1097/CCO.0000000000001121

引用次数: 0

Cancer-associated thrombosis: what is new?

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-16 DOI: 10.1097/CCO.0000000000001125

Isabelle Mahé, Samuel Benarroch, Sadji Djennaoui, Rabiaa Hakem, Abdallah Ghorbel, Hélène Helfer, Jean Chidiac

{"title":"Cancer-associated thrombosis: what is new?","authors":"Isabelle Mahé, Samuel Benarroch, Sadji Djennaoui, Rabiaa Hakem, Abdallah Ghorbel, Hélène Helfer, Jean Chidiac","doi":"10.1097/CCO.0000000000001125","DOIUrl":"10.1097/CCO.0000000000001125","url":null,"abstract":"Purpose of review: The life expectancy of patients suffering from thrombosis associated with cancer has improved significantly, making them a chronic disease. Patients with thrombosis and cancer are fragile. Treated with anticoagulants, they remain at risk of complications.Recent findings: Consequently, news issues emerge for clinical practice: anticoagulation therapy personalization is required to optimize the benefit ratio, involving patient characteristics and cancer characteristics. During follow-up, prediction score are designed and investigated to help identify and discriminate patients at risk of venous thromboembolism recurrences and major bleedings. Considering the improved prognosis of patients with cancer and cancer-associated thrombosis, the question of extended treatment arises, representing a major unmet need to date. Finally, new strategies, in particular anti-XI agents that appear attractive options, are currently being evaluated in the treatment of thrombosis associated with cancer.Summary: The improved prognosis of patients with cancer-associated thrombosis is accompanied by new therapeutic strategies to improve the benefit-risk ratio of anticoagulant treatment in these fragile patients, at risk of both venous thromboembolic recurrence and haemorrhagic complication.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"150-157"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peripheral neuropathy: from guidelines to clinical practise.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-15 DOI: 10.1097/CCO.0000000000001112

Berit Jordan, Franziska Jahn, Karin Jordan

{"title":"Peripheral neuropathy: from guidelines to clinical practise.","authors":"Berit Jordan, Franziska Jahn, Karin Jordan","doi":"10.1097/CCO.0000000000001112","DOIUrl":"10.1097/CCO.0000000000001112","url":null,"abstract":"Purpose of review: Chemotherapy-induced peripheral neuropathy (CIPN) is a substantial adverse effect of anticancer therapy. No effective preventive strategies are established in clinical routine, although some forms of cryotherapy or compression therapy seem to be promising. CIPN is difficult to grade objectively and has mostly relied on a clinician- or patient-based rating that is subjective and not easily reproducible.Recent findings: Recent preclinical and clinical studies showed an indicative hint of serum neurofilaments for axonal damage as a biomarker and might be introduced in clinical practice in the future. Axonal degeneration in toxic neuropathy is triggered by molecular pathways including SARM1. Presence of certain genotypes predispose for developing severe vincristine neuropathy. Still, treatment of CIPN is focused on treating neuropathic pain primarily based on physicians experience. A positive effect of membrane stabilizers such as gabapentinoids could not be shown in a systematic review mostly due to inconsistent study populations. In the treatment and prevention of functional disability, physical exercise including sensorimotor-training and whole-body vibration seems promising.Summary: More research is needed on quantification of biomarkers indicative for axonal degeneration prior to CIPN symptom expression. All these recent findings should support the health-care team for a patient centred treatment approach.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"168-174"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging toxicities in oncology.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-15 DOI: 10.1097/CCO.0000000000001122

Didier Mayeur

引用次数: 0

Genomic and transcriptomic sequencing in prostate cancer.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-02-28 DOI: 10.1097/CCO.0000000000001136

Safiullah Rifai, Azimullah Rifai, Xiaolei Shi, Mohammad Afnan Khan, Wei Guang, Linbo Wang, Luke Tallon, Arif Hussain

{"title":"Genomic and transcriptomic sequencing in prostate cancer.","authors":"Safiullah Rifai, Azimullah Rifai, Xiaolei Shi, Mohammad Afnan Khan, Wei Guang, Linbo Wang, Luke Tallon, Arif Hussain","doi":"10.1097/CCO.0000000000001136","DOIUrl":"https://doi.org/10.1097/CCO.0000000000001136","url":null,"abstract":"Purpose of review: Genomic and transcriptomic sequencing technologies have revolutionized our ability to characterize prostate cancer at the molecular level. The underlying premise of next-generation sequencing technologies and their current and evolving applications in prostate cancer management are provided in the review.Recent findings: Improved methodologies are allowing timely sequencing of the coding regions or both the coding and noncoding regions of the genome to help identify potential mutations and structural variations in the prostate cancer genome, some of which are currently also targetable therapeutically. DNA microarray- based differential gene expression has been supplanted by RNA sequencing (RNA-seq), which not only allows for more accurate quantitation but also nucleotide-level resolution to investigate the entire transcriptome, including alternative gene spliced transcripts and noncoding RNA transcripts, whose full clinical implications have yet to be fully understood and realized. Gene classifier platforms that predict risk of recurrence or metastasis are being incorporated into prostate cancer management algorithms. In the appropriate clinical context, not only somatic but also germline mutation testing is being recommended.Summary: Continued clinical integration of sequencing technologies and ongoing research will lead to improved understanding of prostate cancer biology and prostate cancer treatment.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New trends in supportive care of head and neck cancers.

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-02-24 DOI: 10.1097/CCO.0000000000001135

Ilaria Mascagni, Paolo Bossi

{"title":"New trends in supportive care of head and neck cancers.","authors":"Ilaria Mascagni, Paolo Bossi","doi":"10.1097/CCO.0000000000001135","DOIUrl":"https://doi.org/10.1097/CCO.0000000000001135","url":null,"abstract":"Purpose of review: Supportive care plays a vital role in the management of head and neck cancer (HNC) patients, as the disease often affects a frail and older population that is treated with multiple strategies and is associated with severe symptoms. We will focus on mucositis, dermatitis, dysphagia, pain, cachexia, and infections, as they are among the most common and challenging symptoms encountered.Recent findings: Efforts have focused on multiomics approaches to decipher the complex biological pathways that drive symptom onset and treatment-related toxicities, with the aim of developing novel therapeutic strategies. A notable example is ponsegromab, a monoclonal antibody designed to target cancer cachexia. Other promising areas of research, such as machine-learning models and the role of oral and gut microbiota on cachexia and mucositis, are actively being explored; however, their impact to date remains limited.Summary: In recent years, new knowledge has emerged regarding the underlying causes and predictive models for the supportive care of HNC patients. Unfortunately, this expanding body of knowledge primarily adds to complexity without translating into practical applications or substantial improvements for patients. Future efforts should prioritize the standardization of therapeutic algorithms, and the generation of robust evidence based on existing preclinical models.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0